Antifungal chemotherapies and immunotherapies for the future

Area of Science:

• Mycology
• Infectious Diseases
• Immunology

Background:

• Human fungal pathogens cause diverse infections, from skin diseases to life-threatening invasive conditions, particularly in immunocompromised individuals.
• Fungal pathogens' ability to switch morphotypes complicates treatment and immune responses.
• Current antifungal therapies are limited, necessitating the development of new treatment strategies.

Purpose of the Study:

• To review recent advancements in antifungal drug development and immunotherapy for human fungal infections.
• To highlight novel therapeutic candidates and their mechanisms of action.
• To discuss the emerging role of immunotherapies in managing fungal diseases.

Main Methods:

• Review of recent scientific literature on antifungal drug development and clinical trials.
• Analysis of emerging immunotherapeutic approaches, including monoclonal antibodies and cell-based therapies.
• Synthesis of information on novel antifungal agents targeting specific fungal pathways.

Main Results:

• Several new antifungal agents are in late-stage development, including ibrexafungerp (a 1,3-beta-D-glucan inhibitor) and fosmanogepix (targeting GPI-anchored protein maturation).
• Immunotherapies such as omalizumab (anti-IgE) are increasingly used, with agents targeting IL-4 and IL-5 under evaluation.
• T-cell chimeric antigen receptor (CAR) therapy shows early promise for treating fungal infections.

Conclusions:

• The antifungal armamentarium is expanding with novel drugs and immunotherapies.
• These advancements promise to significantly improve the management of fungal diseases, especially in vulnerable patient populations.
• Future research will likely focus on personalized medicine approaches combining pharmacotherapy and immunotherapy.